公开(公告)号：US20190117798A1

公开(公告)日：2019-04-25

申请号：US16229509

申请日：2018-12-21

Applicant: ModernaTX, Inc.

Inventor： Gilles Besin ,  Stephen Hoge ,  Joseph Senn ,  Kerry Benenato ,  Staci Sabnis

IPC: A61K48/00 ,  C12N15/88 ,  A61K47/10 ,  A61K47/54 ,  A61K31/7115 ,  A61K9/127 ,  A61K47/69 ,  A61K47/60 ,  A61K39/39 ,  C08G65/332 ,  C08G65/333 ,  C08G65/334 ,  C08G65/335 ,  C12N15/117 ,  A61K31/713

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

公开(公告)号：US20190060246A1

公开(公告)日：2019-02-28

申请号：US16184282

申请日：2018-11-08

Applicant: ModernaTX, Inc.

Inventor： Joshua Frederick ,  Ailin Bai ,  Vladimir Presnyak ,  Stephen Hoge ,  Kerry Benenato ,  Iain Mcfadyen ,  Ellalahewage Sathyajith Kumarasinghe ,  Susannah Hewitt

IPC: A61K9/51 ,  C07K14/705 ,  A61P35/00 ,  C07K14/54 ,  C07K14/545 ,  A61K9/00 ,  A61K9/127 ,  A61K38/17 ,  A61K48/00 ,  A61K45/06 ,  A61K39/395 ,  A61K39/39 ,  A61K38/20 ,  A61K39/00

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

公开(公告)号：US10207010B2

公开(公告)日：2019-02-19

申请号：US15674872

申请日：2017-08-11

Applicant: ModernaTX, Inc.

Inventor： Gilles Besin ,  Stephen Hoge ,  Joseph Senn ,  Kerry Benenato ,  Staci Sabnis

IPC: C12N15/88 ,  A61K9/127 ,  A61K48/00 ,  A61K47/54 ,  A61K47/69 ,  A61K47/60 ,  A61K31/713 ,  A61K39/39 ,  A61K47/10 ,  C08G65/332 ,  C08G65/333 ,  C08G65/334 ,  C08G65/335 ,  C12N15/117 ,  A61K31/7115 ,  A61K39/00

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.